# Bioequivalence Study of Cephalexin Suspension 250

> **NCT01767571** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 28 (actual)

## Conditions studied

- Infections, Respiratory Tract

## Interventions

- **DRUG:** Cephalexin 125 mg/5ml
- **DRUG:** Cephalexin 250mg/5ml

## Key facts

- **NCT ID:** NCT01767571
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-01-30
- **Primary completion:** 2011-02-08
- **Final completion:** 2011-02-08
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2017-06-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01767571

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01767571, "Bioequivalence Study of Cephalexin Suspension 250". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01767571. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*